News | January 01, 2026
HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The funding will accelerate Sinopia’s data-driven drug discovery efforts
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Subscribe To Our Newsletter & Stay Updated
